Vascular gene therapy: A reality of the 21st century

Archives of Surgery

Volumn 137, Issue 7, 2002, Pages 854-861

  Zuckerbraun, Brian S ^a   Tzeng, Edith ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOSINE DEAMINASE; FAS LIGAND; FIBROBLAST GROWTH FACTOR; GENE PRODUCT; HIRUDIN; NITRIC OXIDE SYNTHASE; OLIGONUCLEOTIDE; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; TISSUE PLASMINOGEN ACTIVATOR; VASCULOTROPIN; VIRUS VECTOR;

ADJUVANT THERAPY; ATHEROSCLEROSIS; CELL PROLIFERATION; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC PREDISPOSITION; HUMAN; PRIORITY JOURNAL; RESTENOSIS; REVIEW; THROMBOSIS;

ANIMALS; ARTERIOSCLEROSIS; FORECASTING; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; VASCULAR DISEASES;

EID: 0036305926     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. An early history of gene transfer and therapy
2. Genetic exchange in Salmonella
3. A brief history of gene therapy
4. Incorporation of deoxyribonucleic acid by mammalian cells in vitro
5. Recombinant gene expression in vivo within endothelial cells of the arterial wall
6. Site-specific gene expression in vivo by direct gene transfer into the arterial wall
7. Low level in vivo gene transfer into the arterial wall through a perforated balloon catheter
8. The adenoviruses
9. In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes
10. A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase
11. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity
12. Optimizing cardiovascular gene therapy: Increased vascular gene transfer with modified adenoviral vectors
13. Polymercoated adenovirus permits efficient retargeting and evades neutralising antibodies
14. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions
15. Viral vector systems for gene therapy
16. Integration of the adeno-associated virus genome into cellular DNA in latently infected human Detroit 6 cells
17. Optimal techniques for arterial gene transfer
18. Optimization of nonviral gene transfer of vascular smooth muscle cells in vitro and in vivo
19. Fusigenic viral liposome for gene therapy in cardiovascular diseases
20. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides
21. Gene therapy inhibiting neointimal vascular lesion: In vivo transfer of endothelial cell nitric oxide synthase gene
22. Genetic therapies for cardiovascular disease
23. Mechanisms of delivery and local drug delivery technologies
24. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo
25. Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo
26. Improved efficiency of arterial gene transfer by use of poloxamer 407 as a vehicle for adenoviral vectors
27. Antisense oligonucleotides to the p65 subunit of NF-kB inhibit human vascular smooth muscle cell adherence and proliferation and prevent neointima formation in rat carotid arteries
28. VEGF gene transfer reduces intimal thickening via increased production of nitric oxide in carotid arteries
29. Constitutive expression of ph-VEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia
30. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart
31. Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease
32. The delivery of angiogenic factors to the heart by microsphere therapy
33. A call for provisional stenting: The balloon is back!
34. Advances in coronary angioplasty
35. Adenovirus-mediated overexpression of the cyclin/cyclin-dependent kinase inhibitor p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty
36. Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury
37. Adenovirus-mediated transfer of cyclin-dependent kinase inhibitor-p21 suppresses neointimal formation in the balloon-injured rat carotid arteries in vivo
38. Percutaneous delivery of the gax gene inhibits vessel stenosis in a rabbit model of balloon angioplasty
39. Wild-type p53 gene transfer: A novel therapeutic strategy for neointimal hyperplasia after arterial injury
40. Novel chimeric p16 and p27 molecules with increased antiproliferative activity for vascular disease gene therapy
41. p27-p16 Chimera: A superior antiproliferative for the prevention of neointimal hyperplasia
42. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle cell proliferation in vivo
43. Ex vivo gene therapy of human vascular bypass grafts with E2F decoy: The PREVENT single-centre, randomised, controlled trial
44. Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response
45. Adenovirus-mediated delivery of fas ligand inhibits intimal hyperplasia after balloon injury in immunologically primed animals
46. Gene therapy for vascular smooth muscle cell proliferation after arterial injury
47. Inhibition of vascular smooth muscle cell proliferation and neointimal accumulation by adenovirus-mediated gene transfer of cytosine deaminase
48. Nitric oxide in the vasculature: Physiology and pathophysiology
49. Vascular gene transfer of the human inducible nitric oxide synthase: Characterization of activity and effects on myointimal hyperplasia
50. Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo
51. Vascular endothelial growth factor (VEGF) and its receptors
52. Signaling via vascular endothelial growth factor receptors
53. Therapeutic angiogenesis: A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model
54. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs
55. Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: Dose-response effect of basic fibroblast growth factor
56. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model
57. Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts
58. VEGF gene delivery to myocardium: Deleterious effects of unregulated expression
59. VEGF gene therapy: Stimulating angiogenesis or angioma-genesis?
60. In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses
61. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia
62. Correction of hypertriglyceridemia and impaired fat tolerance in lipoprotein lipase-deficient mice by adenovirus-mediated expression of human lipoprotein lipase
63. Hepatic lipase gene therapy in hepatic lipase-deficient mice: Adenovirus-mediated replacement of a lipolytic enzyme to the vascular endothelium
64. Inhibition of intravascular thrombosis and vascular smooth muscle cell proliferation by gene therapy
65. Adenovirus-mediated transfer of tissue-type plasminogen activator augments thrombolysis in tissue-type plasminogen activator-deficient and plasminogen activator inhibitor1-overexpressing mice
66. Adenovirus-mediated local expression of human tissue factor pathway inhibitor eliminates shear stress-induced recurrent thrombosis in the injured carotid artery of the rabbit
67. Retroviral vector-mediated expression of hirudin by human vascular endothelial cells: Implications for the design of retroviral vectors expressing biologically active proteins
68. Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury